Table 3.
Compound | Concentration (mg/mL) | Lifespan Average (days) |
Mean Lifespan Difference (%) |
Healthspan Average (days) |
Mean Healthspan Difference (%) |
---|---|---|---|---|---|
B. rapa 143N5 | control | 46.365 | 16.929 | ||
0.31 | 49.506 | 7 | 19.231 | 13 | |
0.625 | 56.332 ** | 21 | 30.308 | 79 | |
1.25 | 62.747 *** | 35 | 31.714 * | 87 | |
2.5 | 55.891 ** | 20 | 16.000 | −5 | |
5 | 54.611 * | 18 | 23.286 | 37 | |
B. rapa 163N7 | control | 46.365 | 16.929 | ||
0.31 | 58.098 ** | 25 | 40.238 | 137 | |
0.625 | 58.510 * | 26 | 42.679 * | 152 | |
1.25 | 57.908 ** | 26 | 40.302 * | 138 | |
2.5 | 57.917 *** | 25 | 34.574 | 104 | |
5 | 72.066 *** | 55 | 59.854 * | 253 | |
GNA | control | 46.365 | 16.929 | ||
0.0069 | 59.931 *** | 29 | 26.357 | 55 | |
0.0137 | 55.157 *** | 19 | 18.143 | 7 | |
0.0275 | 51.819 ** | 12 | 18.700 | 10 | |
0.055 | 48.241 | 4 | 17.929 | 6 | |
0.11 | 49.828 * | 7 | 17.500 | 3 |
Means were calculated by the Kaplan–Meier method, and significance of the curves was determined by the Log-Rank method (Mantel–Cox). *: significant (p < 0.05), **: highly significant (p < 0.01), ***: very highly significant (p < 0.001).